NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT02304458 2023-10-17Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or SarcomasNational Cancer Institute (NCI)Phase 1/2 Completed140 enrolled 23 charts
NCT01822509 2021-06-24Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell TransplantNational Cancer Institute (NCI)Phase 1 Completed71 enrolled
NCT00060372 2013-03-27Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive CancerNational Cancer Institute (NCI)Phase 1 Completed21 enrolled